WhaleQuant.io

Haleon plc (HLN)

Listed on NYSE • Healthcare / Drug Manufacturers - Specialty & Generic
HLN logo

Overview

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

Explore More Data

Key Information

Symbol: HLN
CEO: Brian James McNamara
Exchange: NYSE
CIK: 0001900304
SEC Filings: View SEC →

Stock Snapshot (Updated: Nov 05 04:00 PM EST)

Price
9.31
Change
-0.01
Change %
-0.11%
Open
9.28
Previous Close
9.32
High
9.36
Low
9.26
Volume
8,035,774
Market Cap
41,793,683,456
EV/EBITDA
14.72

Capital Structure (Updated: Nov 05 04:00 PM EST)

Shares Outstanding
4,452,936,617
FloatShares
8,992,435,200
Float Ratio
201.94%
Shares Short
9,042,468
Short Percent Of Float
The percent of float shares currently sold short. Reflects market sentiment and risk of a short squeeze.
0.20%
Short Ratio
Days needed to cover all short positions. Indicates short-selling pressure.
0.94 trading days
Held Percent Insiders
0.02%
Held Percent Institutions
12.87%

Calendar Events (Upcoming Earnings & Revenue Forecasts)

Earnings
Earnings Date 2025-07-31
Earnings Call 2025-07-31
Avg EPS Estimate 0
Low EPS Estimate 0
High EPS Estimate 0
Revenue
Avg Revenue Forecast 2,763,666,670
Low Revenue Forecast 2,751,000,000
High Revenue Forecast 2,777,000,000

HLN Liquidity Indicators Shows key metrics that reflect cash availability and short-term payment ability

Field Value Description
Cash Holdings$676,000,000Cash on hand, which directly shows a company's ability to meet short-term obligations.
Quick Ratio0.605The quick ratio, which excludes inventory, measures short-term solvency; a value above 1 is considered relatively safe.
Current Ratio0.87The current ratio, calculated as current assets divided by current liabilities; the higher the value, the better the liquidity.
Total Debt$8,544,999,936Total liabilities, used together with cash and liquidity ratios to assess debt burden.

HLN Profitability Indicators Shows key metrics that reflect overall earnings, margins, and core business profitability

Field Value Description
EBITDA$2,625,999,872EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which measures the profitability of core operations.
Operating Cash Flow$2,486,000,128Operating cash flow, which reflects a company's cash-generating ability.
Free Cash Flow$1,922,749,952Free cash flow, after deducting capital expenditures, which can be used for dividends or reinvestment.
Gross Margin63.56%Gross margin; a higher value indicates stronger product profitability.
Operating Margin22.21%Operating margin; slightly negative, indicating high operating costs.
Profit Margin13.81%Net profit margin, which reflects overall profitability.

HLN Leverage & Financial Health Indicators Shows key metrics that reflect debt levels, liquidity, and overall financial stability

Field Value Description
Debt/Equity Ratio53.41%Low leverage level, indicating the company has low debt pressure.
Total Debt$8,544,999,936Used together with cash and EBITDA to assess debt-paying ability.

HLN Growth Indicators Shows key financial metrics that reflect profitability, cash flow, and business expansion

Field Value Description
Revenue Growth (YoY)-1.30%Rapid revenue growth, indicating fast business expansion.
Earnings Growth (YoY)34.80%Significant EPS growth, indicating rapid improvement in profitability.

Financial Data for HLN (Key ratios, margins, and cash flow)

Field Value Description
Current Price$9.31Latest stock trading price
Price Target (High)$13.6Analyst highest expected price
Price Target (Low)$10Analyst lowest expected price
Price Target (Average)$11.56Average target price across analysts
Price Target (Median)$11.2Median of target prices
Average Rating Score1.8Average analyst rating (1=Strong Buy, 5=Sell)
Consensus RecommendationbuyConsensus rating
Analyst Coverage Count5Number of analysts providing estimates
Cash Holdings$676,000,000Total cash held by the company
Cash per Share$0.07Cash value per outstanding share
Total Debt$8,544,999,936Company's total debt
Quick Ratio0.605Ability to cover short-term liabilities (excludes inventory)
Current Ratio0.87Overall short-term liquidity
Debt/Equity Ratio53.41%Leverage ratio: Debt / Equity
EBITDA$2,625,999,872Earnings before interest, taxes, depreciation & amortization
Total Revenue$11,018,999,808Total company revenue
Revenue per Share$2.432Total revenue divided by shares outstanding
Gross Profit63.56%Revenue minus cost of goods sold
Return on Assets4.61%Net income / Total assets
Return on Equity9.38%Net income / Shareholder equity
Earnings Growth (YoY)34.80%Year-over-year EPS growth
Revenue Growth (YoY)-1.30%Year-over-year revenue growth
Gross Margin63.56%Gross profit / Total revenue
EBITDA Margin23.83%EBITDA / Revenue
Operating Margin22.21%Operating income / Revenue
Profit Margin13.81%Net income / Revenue
Free Cash Flow$1,922,749,952Cash left after capital expenditures
Operating Cash Flow$2,486,000,128Cash from core business operations
CurrencyUSDReported in US dollars
Last Updated2025-11-05Data source from Yahoo